Indication: Multiple Myeloma
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Sub-indication: Hematological Malignancies
Study Type: Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Sponsor: Janssen Research & Development
Email for more information: Heme-NCIResearch@nortonhealthcare.org
